Pygeum Bark Powder
Also known as: Prunus africana, African cherry, Pygeum
Overview
Pygeum africanum, also known as African cherry, is a plant native to Africa. Its bark extract is used as a phytotherapeutic agent, primarily for treating benign prostatic hyperplasia (BPH). The extract is rich in sterols, particularly beta-sitosterol, and other compounds like docosyl ferulate. It aims to alleviate lower urinary tract symptoms (LUTS) associated with BPH. The extract is often standardized to contain a minimum of 13% beta-sitosterol. Research on Pygeum africanum is moderate, with several randomized controlled trials (RCTs) and systematic reviews indicating improvements in urologic symptoms and flow measures. However, more robust and long-term studies are needed to fully establish its effectiveness and safety.
Benefits
Pygeum africanum extract significantly improves urologic symptoms and flow measures in men with BPH. Studies show a reduction in nocturia by 19%, residual urine volume by 24%, and an increase in peak urine flow by 23% compared to placebo. Men using Pygeum africanum are more than twice as likely to report an improvement in overall symptoms (Risk Ratio = 2.1, 95% CI: 1.4 to 3.1). The extract also exhibits anti-inflammatory potential, as demonstrated by in vitro studies showing reduced cytokine release from stimulated human peripheral blood mononuclear cells. These benefits are primarily observed in men with symptomatic BPH, with effects typically noticeable within a few months.
How it works
The exact mechanism of action of Pygeum africanum is not fully understood, but it is believed to involve anti-inflammatory and hormonal effects. The extract may inhibit 5-alpha-reductase, reduce inflammation, and improve bladder and prostate function. Beta-sitosterol and other sterols in the extract may target androgen receptors and enzymes involved in prostate health. It interacts with the urinary and reproductive systems, particularly affecting the prostate gland. While the bioavailability of the active components is not extensively studied, the standardized extract ensures consistent levels of key sterols.
Side effects
Pygeum africanum is generally well-tolerated, with adverse effects similar to those of placebo. There are no commonly reported side effects at a frequency greater than 5%. Mild gastrointestinal symptoms may occur but are not frequently reported (1-5%). No significant rare side effects have been documented in the reviewed studies (<1%). There is limited data on interactions with other medications, but it is generally used without significant concerns. No specific contraindications are noted, but caution should be exercised in patients with severe prostate conditions or those undergoing surgery. The extract is specifically used for men with BPH; its use in other populations is not well-studied.
Dosage
Typical dosages of Pygeum africanum range from 50 mg to 100 mg per day of the standardized extract, containing at least 13% beta-sitosterol. The timing of administration is not critical, but it is usually taken once or twice daily. Capsules are a common form, ensuring consistent dosing of the standardized extract. There is no established maximum safe dose, but doses above 100 mg per day are not typically studied. No specific cofactors are required for the efficacy of Pygeum africanum.
FAQs
How long does it take to see benefits?
Benefits from Pygeum africanum can typically be observed within a few months of consistent use.
Is Pygeum africanum safe?
Pygeum africanum is generally well-tolerated, with adverse effects similar to those of placebo in studies.
When should I take Pygeum africanum?
It can be taken once or twice daily, but the timing is not critical for its effectiveness.
What improvements can I expect?
Users may experience improvements in urologic symptoms, reduced nocturia, and increased urine flow.
Is Pygeum africanum a cure for BPH?
No, Pygeum africanum is a symptomatic treatment for BPH and not a cure for the condition.
Research Sources
- https://www.mdpi.com/1422-0067/25/15/8298 – This in vitro study found that Pygeum africanum bark extract reduced cytokine release from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. The study suggests an anti-inflammatory potential of the extract, providing mechanistic insights into its possible effects on prostate health. However, the findings are limited by the in vitro nature of the study and lack direct clinical relevance.
- https://pubmed.ncbi.nlm.nih.gov/11869585/ – This study investigated the effects of Pygeum africanum on lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). The research suggests that Pygeum africanum may offer symptomatic relief for men experiencing LUTS due to BPH, potentially improving their quality of life. Further research is needed to confirm these findings and determine the optimal dosage and duration of treatment.
- https://pubmed.ncbi.nlm.nih.gov/11099686/ – This study examined the efficacy of Pygeum africanum in treating benign prostatic hyperplasia (BPH). The results indicated that Pygeum africanum can improve urologic symptoms and flow measures in men with BPH. The study contributes to the evidence supporting the use of Pygeum africanum as a complementary therapy for managing BPH symptoms.
- https://patents.google.com/patent/US20130236574A1/en – This patent describes a method for preparing a standardized extract of Pygeum africanum. The method aims to ensure consistent levels of active compounds, such as beta-sitosterol, in the extract. This standardization is important for ensuring the efficacy and reliability of Pygeum africanum products used for treating BPH.
- https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001044/abstract – This Cochrane review analyzed multiple randomized controlled trials (RCTs) involving men with symptomatic BPH. The review found that Pygeum africanum provided a moderately large improvement in urologic symptoms and flow measures compared to placebo. However, the authors noted limitations in the included studies, such as small sample sizes and short durations, highlighting the need for further robust trials to establish long-term effectiveness.